Skip to main content
Clinical Trials/NCT02195297
NCT02195297
Completed
Phase 3

Clinical and Instrumental Evaluation of the Activity of a Pharmacological "Anticellulitis" Product vs. a Reference Product on the Market: Comparison Within Subjects (Double Blind Study)

Derming SRL0 sites22 target enrollmentSeptember 2013
ConditionsHealthy

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Healthy
Sponsor
Derming SRL
Enrollment
22
Primary Endpoint
Morphometric evaluations: change from baseline (T2 and T4 vs. T0)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Aim of this study was to evaluate by clinical, morphometric and non invasive instrumental evaluations the activity of an "anticellulitis" cosmetic product vs a reference product of the market (comparison within subjects), applied once a day, for an uninterrupted period of 4 weeks, on 22 female healthy volunteers with low/moderate oedematous - fibrosclerotic lipodystrophy on the thighs.

It was also aim of the study to evaluate cosmetic acceptability by the volunteers and products efficacy and tolerance both by investigator and volunteers.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
October 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • female volunteers
  • volunteers aged more than 18 years old
  • volunteers with low/moderate oedematous - fibrosclerotic lipodystrophy on the thighs
  • volunteers with no weight variation (± 1.5 kg) during the last month preceding the study inclusion
  • volunteers with regular menstrual cycle (28-32 days) or in menopause from at least 2 years
  • volunteers who are giving a written informed consent.

Exclusion Criteria

  • pregnancy
  • lactation
  • smoke (admitted 10 cigarettes/day)
  • assumption of alcoholic drinks/wine/beer (admitted up to 125 ml for meal)
  • oral contraceptive/replacement therapy started less than 1 year ago
  • alimentary diet
  • change in the normal habits in the last month (unusual physical activity)
  • use of any product or weight-loss treatment (manual or instrumental massage) on skin test areas during the last month
  • use of any drug able to cause a weight body variation
  • presence of clinically important vascular disorders

Outcomes

Primary Outcomes

Morphometric evaluations: change from baseline (T2 and T4 vs. T0)

Time Frame: after 2 and 4 week-treatment

All the measures were performed in standard conditions at level of the thigh (III superior, III middle and inferior), thanks to a specific electro-optical system.

Secondary Outcomes

  • Skin plastoelasticity: change from baseline (T2 and T4 vs. T0)(after 2 and 4 week-treatment)
  • Thermography evaluation: change from baseline (T2 and T4 vs. T0)(after 2 and 4 week-treatment)
  • Ultrasonographic evaluations: change from baseline (T2 and T4 vs. T0)(after 2 and 4 week-treatment)
  • Optical densitometry: change from baseline (T2 and T4 vs. T0)(after 2 and 4 week-treatment)
  • Clinical evaluations: change from baseline (T2 and T4 vs. T0)(after 2 and 4 week-treatment)
  • Tissue dielectric constant of deep skin layers: change from baseline (T2 and T4 vs. T0)(after 2 and 4 week-treatment)

Similar Trials